Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.74 |
| ▸ | LMNA | P02545 | 4/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.74 |
| ▸ | MEN1 | O00255 | 3/20 | 0.74 |
| ▸ | NPC1 | O15118 | 2/20 | 0.74 |
| ▸ | RAB9A | P51151 | 2/20 | 0.74 |
| ▸ | GAA | P10253 | 2/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.56 |
| ▸ | ESR1 | P03372 | 1/20 | 0.56 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | PDE6D | O43924 | 1/20 | 0.54 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.54 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29475390 | 1.00 | KDM4E (0.74) | KDM4ELMNAKMT2AMEN1NPC1 | |
| SCHEMBL5702588 | 0.91 | KDM4E (0.64) | KDM4ELMNAKMT2AMEN1NPC1 | |
| SCHEMBL9520082 | 0.85 | KDM4E (0.71) | KDM4ELMNAKMT2AMEN1NPC1 | |
| SCHEMBL12325283 | 0.85 | KMT2A (1.00) | KDM4ELMNAKMT2AMEN1NPC1 | |
| SCHEMBL28392218 | 0.81 | KDM4E (0.65) | KDM4ELMNAKMT2AMEN1NPC1 | |
| SCHEMBL12325734 | 0.81 | KDM4E (0.65) | KDM4ELMNAKMT2AMEN1NPC1 | |
| SCHEMBL14922007 | 0.80 | KDM4E (0.69) | KDM4ELMNAKMT2AMEN1NPC1 | |
| SCHEMBL3639863 | 0.79 | KDM4E (1.00) | KDM4ELMNAKMT2AMEN1NPC1 | |
| SCHEMBL12325957 | 0.79 | KDM4E (0.68) | KDM4ELMNAKMT2AMEN1NPC1 | |
| SCHEMBL29588162 | 0.79 | KDM4E (1.00) | KDM4ELMNAKMT2AMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0983334-A1 | ENZYMATIC BLEACHING SYSTEM CONTAINING NEW COMPOUNDS FOR INTENSIFYING ENZYMATIC ACTION | Call, Krimhild (DE) | 2000-03-08 | — | — | EP | claimed |
| WO-1999001607-A2 | ENZYMATIC OXIDATION SYSTEM WITH NOVEL ENZYMATIC-EFFECT ENHANCING COMPOUNDS | CALL, KRIMHILD (DE) | 1999-01-14 | — | — | WO | claimed |
| WO-1998051772-A1 | ENZYMATIC BLEACHING SYSTEM CONTAINING NEW COMPOUNDS FOR INTENSIFYING ENZYMATIC ACTION | CALL, KRIMHILD (DE) | 1998-11-19 | — | — | WO | claimed |
| US-20260137765-A1 | METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STXB) MONOMERS AND OLIGOMERS, AND USES THEREOF | INSTITUT CURIE (FR) | 2026-05-21 | — | — | US | disclosed |
| US-12527854-B2 | Methods of producing Shiga toxin B-subunit (STxB) monomers and oligomers, and uses thereof | INSTITUT CURIE (FR) | 2026-01-20 | — | — | US | disclosed |
| US-20230331751-A1 | STEREOSELECTIVE MANUFACTURE OF SELECTED PURINE PHOSPHORAMIDATES | Atea Pharmaceuticals, Inc. (US) | 2023-10-19 | — | — | US | disclosed |
| EP-4200309-A1 | STEREOSELECTIVE MANUFACTURE OF SELECTED PURINE PHOSPHORAMIDATES | ATEA Pharmaceuticals, Inc. (US) | 2023-06-28 | — | — | EP | disclosed |
| CN-115884977-A | Stereoselective preparation of selected purine phosphoramidates | 阿堤亚制药公司 | 2023-03-31 | — | — | CN | disclosed |
| US-20220233673-A1 | METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STxB) MONOMERS AND OLIGOMERS, AND USES THEREOF | INSTITUT CURIE (FR) | 2022-07-28 | — | — | US | disclosed |
| EP-3980057-A1 | METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STXB) MONOMERS AND OLIGOMERS, AND USES THEREOF | Institut Curie (FR) | 2022-04-13 | — | — | EP | disclosed |
| WO-2022040473-A1 | STEREOSELECTIVE MANUFACTURE OF SELECTED PURINE PHOSPHORAMIDATES | Atea Pharmaceuticals, Inc. (US) | 2022-02-24 | — | — | WO | disclosed |
| US-6023000-A | Process for the preparation of aldehydes and ketones | Consortium fur elektrochemisch Industrie GmbH (DE) | 2000-02-08 | — | — | US | disclosed |
| EP-0913382-A1 | Process for the preparation of aldehydes and ketones | Consortium für elektrochemische Industrie GmbH (DE) | 1999-05-06 | — | — | EP | disclosed |
| EP-0905306-A1 | Multicomponent system for modifying, decomposing or bleaching lignin or lignin-containing materials and method of using this system | Consortium für elektrochemische Industrie GmbH (DE) | 1999-03-31 | — | — | EP | disclosed |
| EP-0885868-A1 | Oxidation-process for the production of aldehydes and ketones in the presence of nitrogen-containing compounds | Consortium für elektrochemische Industrie GmbH (DE) | 1998-12-23 | — | — | EP | disclosed |
| EP-0882814-A1 | System and process for the electrochemical cleavage of compounds | Consortium für elektrochemische Industrie GmbH (DE) | 1998-12-09 | — | — | EP | disclosed |
| EP-0745154-B1 | MULTICOMPONENT SYSTEM FOR MODIFYING, DECOMPOSING OR BLEACHING LIGNIN, LIGNIN-CONTAINING MATERIALS OR SIMILAR SUBSTANCES AND METHOD OF USING THIS SYSTEM | LIGNOZYM GMBH (DE) | 1998-09-16 | — | — | EP | disclosed |
| EP-0745154-A1 | MULTICOMPONENT SYSTEM FOR MODIFYING, DECOMPOSING OR BLEACHING LIGNIN, LIGNIN-CONTAINING MATERIALS OR SIMILAR SUBSTANCES AND METHOD OF USING THIS SYSTEM | Lignozym GmbH (DE) | 1996-12-04 | — | — | EP | disclosed |
| WO-1996018770-A2 | MULTICOMPONENT SYSTEM FOR MODIFYING, DECOMPOSING OR BLEACHING LIGNIN, LIGNIN-CONTAINING MATERIALS OR SIMILAR SUBSTANCES AND METHOD OF USING THIS SYSTEM | LIGNOZYM GMBH (DE) | 1996-06-20 | — | — | WO | disclosed |
| EP-0717143-A1 | Multicomponents system for modifying decomposing or bleaching of lignin or materials containing it or similar components and the way to use it | Lignozym GmbH (DE) | 1996-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12527854-B2 | Methods of producing Shiga toxin B-subunit (STxB) monomers and oligomers, and uses thereof | STXBP1, RNGTT, UPF1 | KDM4E 2432/4885LMNA 757/4885KMT2A 1584/4885 |
| US-20260137765-A1 | METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STXB) MONOMERS AND OLIGOMERS, AND USES THEREOF | STXBP1, HBB, UPF1 | KDM4E 2972/4885LMNA 1243/4885KMT2A 1769/4885 |
| US-20230331751-A1 | STEREOSELECTIVE MANUFACTURE OF SELECTED PURINE PHOSPHORAMIDATES | NUDT1, PNP, ATIC | KDM4E 3678/4885LMNA 4604/4885KMT2A 3176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.